key: cord-0790816-6jz9ef8r
authors: Ammann, Sandra; Lehmberg, Kai; zur Stadt, Udo; Janka, Gritta; Rensing‐Ehl, Anne; Klemann, Christian; Heeg, Maximilian; Bode, Sebastian; Fuchs, Ilka; Ehl, Stephan
title: Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T‐cell activation, differentiation and repertoire
date: 2017-01-03
journal: Eur J Immunol
DOI: 10.1002/eji.201646686
sha: 2774b6c2b3acf470569fd6b372f5b4edb006a811
doc_id: 790816
cord_uid: 6jz9ef8r

Hemophagocytic lymphohistiocytosis (HLH) is a life‐threatening inflammatory syndrome characterized by hyperactivation of lymphocytes and histiocytes. T cells play a key role in HLH pathogenesis, but their differentiation pattern is not well characterized in patients with active HLH. We compared T‐cell activation patterns between patients with familial HLH (1°HLH), 2°HLH without apparent infectious trigger (2°HLH) and 2°HLH induced by a viral infection (2°V‐HLH). Polyclonal CD8(+) T cells are highly activated in 1°HLH and 2°V‐HLH, but less in 2°HLH as assessed by HLA‐DR expression and marker combination with CD45RA, CCR7, CD127, PD‐1 and CD57. Absence of increased HLA‐DR expression on T cells excluded active 1° HLH with high sensitivity and specificity. A high proportion of polyclonal CD127(−)CD4(+) T cells expressing HLA‐DR, CD57, and perforin is a signature of infants with 1°HLH, much less prominent in virus‐associated 2°HLH. The similar pattern and extent of CD8(+) T‐cell activation compared to 2° V‐HLH is compatible with a viral trigger of 1°HLH. However, in most 1°HLH patients no triggering infection was documented and the unique activation of cytotoxic CD4(+) T cells indicates that the overall T‐cell response in 1°HLH is different. This may reflect different pathways of pathogenesis of these two HLH variants.

Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome currently defined by a number of clinical and laboratory features that can develop in the context of various diseases [1] . About a third of patients with HLH have a monogenetic predisposition affecting lymphocyte cytotoxicity, including familial hemophagocytic syndromes (FHL2-5) [2] , several albinism syndromes with immunodeficiency (GS2, CHS, HPS2) [3] and X-linked lymphoproliferative syndromes (XLP1+2) [4] . These conditions can be summarized as 1°HLH. EBV infection is a key trigger of the HLH syndrome in XLP, but EBV and other viral or bacterial infections can also trigger disease in patients with FHL or albinism syndromes [5] . However, in most FHL patients under the age of one year routine microbiological investigations do not detect an infectious agent in our German cohort. Therefore, it remains unclear if and which trigger is required for disease manifestation in these patients.

In the other two thirds of HLH cases, no clear genetic predisposition can be identified apart from a few patients with inborn errors of metabolism or primary immunodeficiencies (2°HLH) [1, 6] . A possible contribution of monoallelic mutations in FHL associated genes remains debated [7, 8] (Ammann et al., in preparation) . About a quarter of 2°HLH patients have underlying diseases associated with immune activation such as autoimmune or autoinflammatory disease or malignancy [9] . In these cases, infections, in particular with viruses, are frequent additional disease triggers. Secondary HLH induced by various infections, most prominently EBV and leishmania [1] , without obvious underlying disease, are responsible for an additional 50% of cases with 2°HLH. In the remaining quarter of 2°HLH in our German cohort, neither a clear disease-associated condition nor a triggering infection is reported (Ammann et al., in preparation) .

Hyperactivation of lymphocytes and histiocytes are eponymous features of HLH. This is reflected by infiltrations of T cells and macrophages in HLH target organs such as the liver [10] , bone marrow, and brain, as well as by the detection of excessive levels of inflammatory cytokines produced by these cells [11] . Studies in perforin knock-out mice have shown that T cells, mainly CD8 + T cells are critical for disease pathogenesis [12] . Both CD4 + and CD8 + T cell populations are significantly more activated in virusinfected mice with genetic defects of cytotoxicity than in virusinfected controls [13] . These studies have defined T-cell hyperactivation as a key feature of 1°HLH providing a rationale for treatment approaches mainly targeting activated T cells such as ATG [14] , etoposide [15] or alemtuzumab [16] . It remains far from clear, however, whether activated T cells are as important in 2°HLH. Elevated sCD25 is frequently taken as indirect evidence of T-cell activation in HLH, but CD25 can also be shed from other cells including non-hematopoetic cells [17, 18] and its correlation to cellular markers of T-cell activation remains to be examined.

We hypothesize that the activation and differentiation phenotype of T-cell populations in the different human HLH variants may mirror their involvement in disease pathogenesis. Underlying defects in cytotoxicity may lead to a phenotypic "footprint" in the T-cell compartment. Furthermore, patterns of T-cell activation may differ between virus-triggered and non-infection-associated HLH. Hence, we analyzed markers of T-cell activation and differentiation in patients with 1°HLH in comparison to patients with non-infection associated 2°HLH and patients with virus-triggered 2°HLH (2°V-HLH). We show that despite similarities to 2°V-HLH in CD8 + T cells, the activation profile of CD4 + T cells is a unique signature of 1°HLH and may indicate a different pathogenesis.

Between 2012 and 2015, we recruited 93 patients who fulfilled at least 5/8 clinical HLH criteria into this study (Supporting Information Table 1A ). 31 patients were classified as 1°HLH. This included 11 patients with FHL-2, 12 patients with FHL-3, 1 patient with FHL-4, 4 patients with FHL-5, two patients with GS2 and 1 patient with CHS. Only three of these patients had proven viral infections, two with EBV and one with CMV. Thirty patients were classified as 2°HLH, all without infections. They included 12 patients with MAS, 1 patient with metabolic disease, 1 patient with osteopetrosis and A91V mutation in perforin and 16 patients who could not be assigned a clear underlying disease. Thirty-two patients were classified as 2°V-HLH, 4 of them had underlying diseases. Among these 32 patients, 19 had evidence of acute EBV infection by serology and/or PCR. Other acute viral infections diagnosed in the context of HLH by PCR included CMV (4), ParvovirusB19 (3), Adenovirus (2), HHV6 (2), Coronavirus (1), Parainfluenza (1), HSV (1), RSV (1). Two patients had positive PCR for two viruses (HHV6+CMV and EBV+CMV) (Supporting Information  Table 1a ). HLA-DR expression on CD3 + CD8 + and CD3 + CD4 + T cells and sCD25 levels (by chemoluminescence) from the serum, were measured in all 93 patients, since the age-dependent variability of HLA-DR expression and sCD25 level in healthy donors is limited. For all other investigations, we only included patients younger than one year (18 1°HLH, 6 2°HLH, 6 2°V-HLH) because of the extensive variability in T-cell differentiation marker expression beyond that age.

While naïve human T cells do not express MHC class II molecules such as HLA-DR, TCR mediated activation as well as a number of cytokines, in particular type I and type II interferons, but also IL-2, IL-12 and GM-CSF can upregulate HLA-DR expression [19, 20] . We analyzed HLA-DR expression on CD4 + and CD8 + T cells in patients with active HLH (n = 93) in the absence of immunosuppressive therapy. This included patients with 1°(n = 31) and 2°HLH with (n = 32) or without documented viral infection (n = 30) as summarized in Table 1 . Irrespective of age, healthy donors show HLA-DR expression on CD4 + or CD8 + Percentage of HLA-DR + CD8 + T cells among total CD3 + CD8 + T cells (upper panel) and HLA-DR + CD4 + T cells among total CD3 + CD4 + T cells (lower panel) in the indicated groups of patients. Differences between the three groups were analyzed by Mann-Whitney U test. Only significant differences are shown (defined as ***for p ࣘ 0.0005 and ****for p < 0.0001). (C) ROC curves showing the cut-off for optimal sensitivity and specificity for % HLA-DR + CD8 + (upper panel) and CD4 + T cells (lower panel) for patients with any form of HLH and controls. (D) Serum level of soluble CD25 (sCD25) were measured by Chemiluminescence Immunoassay (CLIA) patients with 2°HLH (n = 23), 2°V-HLH (n = 25) and 1°HLH (n = 27) given in U/mL. Differences between the three groups were analyzed by Mann-Whitney U test mean +/− SD is shown. Only significant differences are shown (defined as ***for p ࣘ 0.0005 and ****for p < 0.0001). T cells below 12% [21, 22] (Fig. 1A) . The proportion of T cells with increased HLA-DR expression was significantly higher in patients with HLH. Among CD8 + T cells, this was moderate (mean 21%) in patients with 2°HLH in the absence of an apparent infection, but much higher (median 61.5%) in patients with 2°HLH triggered by a virus infection (2°V-HLH) as well as in patients with 1°HLH (mean 64.4%) (Fig. 1B, upper panel) . T-cell activation was not significantly different between the 19 patients with EBVassociated HLH and the 13 patients with HLH in the context of other viral infections (data not shown). Interestingly, the pattern of HLA-DR expression was different among CD4 + T cells, which showed a moderate increase in the fraction of HLA-DR expressing cells in both groups of 2°HLH patients (mean 8.7 and 12%), while it was much higher (mean 37.8%) in patients with 1°HLH ( Fig. 1B, lower panel) . We performed ROC analysis to determine the cut-off for optimal sensitivity and specificity of HLA-DR in discriminating between healthy donors and patients with any form of active HLH. A percentage of HLA-DR expression below 14% among CD8 + T cells and 5% among CD4 + T cells achieved sensitivities and specificities well above 80%. However, HLA-DR expression could not differentiate between 1°and 2°V-HLH (Fig. 1C ).

An increased serum level of soluble IL-2 receptor α chain (sCD25) is a characteristic marker of immune activation in HLH. sCD25 is shed from activated T cells, but is also expressed by NK cells, B cells, macrophages, dendritic cells and non-immune cells such as fibroblasts and pulmonary endothelial cells [23] . It therefore remains unclear to which extent sCD25 levels reflect T-cell activation in different HLH conditions. sCD25 serum levels were highly elevated in all three groups of patients. However, 1°HLH patients had significantly higher serum levels of sCD25 (all above 6000 U/mL) compared to both 2°HLH groups (Fig. 1D ). Unexpectedly, there was a poor correlation between HLA-DR expression on CD4 + or CD8 + cells and sCD25 levels in all patient groups ( Fig. 1 E,F) . The only significant correlation was observed between the fraction of HLA-DR + CD8 + T cells and sCD25 levels in patients with 1°HLH ( Fig. 1F ). This poor correlation could either be explained by the fact that we only looked at the percentage of circulating T cells and not at their absolute numbers, including activated T cells in lymphoid tissues, or point to other sources of sCD25 than T cells.

We then addressed the question whether the differences in HLA-DR expression were reflected in the T-cell differentiation pattern in the different subtypes of HLH. According to Appay [24] , naïve T cells were defined as CD45RA + CCR7 + , central memory cells (TCM) as CD45RA − CCR7 + , effector-memory (TEM) cells as CD45RA − CCR7 − and terminally differentiated or effector T (TE) cells as CD45RA+CCR7-( Fig. 2A) . Since the variability of the percentage of naïve and memory cells increases with age [25] , we restricted our analysis to patients and controls younger than one year of age (Supporting Information Table 1B ). Patients with 2°HLH without apparent infection (n = 6) had about 90% naïve CD4 + and CD8 + T cells, similar to healthy controls and to asymptomatic patients with 1°HLH. In contrast, the majority of CD8 + T cells had an effector-memory phenotype in about 60% of patients with 1°HLH and 50% of patients with 2°V-HLH (n = 6). Advanced T-cell differentiation was less pronounced among CD4 + T cells, where a predominant effector-memory phenotype was observed in 14.5% in patients with 2°V-HLH. Notably, this was more pronounced in patients with 1°HLH (35%) (Fig. 2B) . Overall, the pattern of T-cell activation was variable between different individuals (Supporting Information. Fig. 1 ), probably favored by the fact that samples were taken at different time points in the course of the disease.

Two further prominent phenotypic changes after T-cell activation are downregulation of the IL-7 receptor alpha chain (CD127) [24, 25] and upregulation of the inhibitory receptor PD-1. Consistent with the results obtained above, patients with 2°HLH without a viral trigger had low percentages of PD-1 + expressing CD4 + or CD8 + T cells, similar to healthy donors or asymptomatic patients with 1°HLH (Fig. 3C, D) . In contrast, in patients with 1°HLH or patients with 2°V-HLH, the percentage of PD1 + , as well as CD127 − cells was highly increased (Fig. 3 A-D) . Again, changes in the CD4 + T-cell population were more pronounced in 1°HLH, although the difference to 2°V-HLH only reached statistical significance for CD127 expression (Fig. 3B) .

CD57 is an epitope on human T cells that strongly correlates with their proliferative history [26] . CD57 + T cells produce cytokines and are cytotoxic [27] , but poorly proliferate in vitro [26] . As expected, almost no CD57 + T cells were detected in healthy infants or asymptomatic 1°HLH patients and this was similar in patients with 2°HLH (Fig. 3 E+F) . In contrast, CD57 + T cells were increased in patients with virus-induced 2°V-HLH and particularly in 1°HLH (Fig. 3F) . Again, among CD4 + T cells, CD57 expressing cells were significantly higher in 1°HLH as compared to 2°V-HLH.

Of note, all infants classified as 2°HLH without apparent microbial trigger had little evidence of T-cell activation (HLA-DR and differentiation markers), despite the fact that they fulfilled current clinical diagnostic HLH including sCD25 levels between 5,000-12,000 U/mL.

Perforin expression is mainly induced after activation of CD8 + T cells but can also be detected in terminally differentiated human CD4 + T cells during chronic infections [28, 29] . We analyzed perforin expression in our patient cohort. Besides all infants with degranulation defects, we also included 2 patients with biallelic perforin mutations, who had reduced, but sufficient residual protein expression to separate perforin-positive from perforinnegative T cells. While the proportion of perforin expressing CD8 + T cells was low in controls, it was variably elevated in patients with 2°HLH, irrespective of a viral trigger (Fig. 4 A, B) . The highest proportion of perforin-expressing CTL was observed in patients with 1°HLH. This difference was much more pronounced in the CD4 compartment (Fig. 4B) . Perforin-positive T cells, in particular CD4 + T cells, are usually characterized by downregulation of CD27 and CD28 [28] . Interestingly, among the 1°HLH infants, in 6/10 CCR7 − CD45RA − T cells (representing the perforin + population as shown in 4/4 patients) had a CD27 + CD28 + and 4/10 a mixed CD27 + CD28 + and CD27 − CD28 + phenotype (Fig. 4C+D) , indicating that these cells represent early/intermediate differentiated acute effector CD4 + T cells [24, 28] .

Strong antigen-specific activation of T cells can result in repertoire alterations due to preferential expansion of antigenspecific T-cell populations [29] . We analyzed the T-cell receptor repertoire in HLH patients using antibodies to the 24 most common TCR V-beta chains. Patients classified as 2°HLH without apparent infectious trigger showed a V beta repertoire among CD4 + and CD8 + T cells that was similar to that of control infants (Fig. 5) . Compared to these controls, patients with 2°V-HLH had more V beta chain populations that were represented more than 2 standard deviations above the mean of normal donors (mean + 2 SD), indicating a moderate perturbation of the normal repertoire. This picture was similar in 6 patients with 1°HLH. In a single patient, we found a strong dominance of a V beta 3 expressing CD8 + T-cell population (Fig. 5) . The TCR repertoire analysis did not reveal obvious general differences between 1°and 2°V-HLH.

To characterize patterns of immune activation in patients with different forms of HLH, we performed a phenotypic comparison of their T-cell compartments. Our observations (summarized in Table 1 ) support three main conclusions: First, T-cell activation is a hallmark of many defined forms of HLH, most prominent in 1°HLH and 2°V-HLH, but also in other forms of 2°HLH including MAS. However, disease states meeting all current diagnostic criteria for the syndrome of HLH can occur without obvious evidence of T-cell activation. Second, the pattern of CD8 + T-cell activation in 1°HLH, in most cases in the apparent absence of a microbial trigger, is very similar to that in 2°HLH triggered by a viral infection. Third, strong activation of cytotoxic CD4 + T cells is a signature of 1°HLH that is much less pronounced in virus-triggered 2°HLH. These findings are relevant for understanding the pathogenesis of different HLH variants and have implications for their differential diagnosis.

Previous studies have reported increased HLA-DR expression on T cells [30] [31] [32] and a mild decrease in the percentage of CD45RA + CD4 + T cells [31, 33] in children with active HLH. However, this has not been analyzed in larger cohorts with clearly defined disease subtypes and the current possibilities to confirm genetic disease. Here, we observed a strong activation of the CD8 + T-cell compartment in patients with 2°V-HLH and 1°HLH, while this was less pronounced in patients with 2°HLH in the absence of infections, including patients with MAS. In some infants, disease states fulfilling all current clinical criteria of 2°HLH even occurred in the absence of any measurable T-cell activation. In patients with 1°HLH and 2°V-HLH, activation was polyclonal with a mild perturbation of the normal repertoire. A large fraction of CD8 + T cells had a CCR7 − CD45RA − effector memory phenotype that was associated with downregulation of CD127, and upregulation of HLA-DR, PD-1, CD57, and perforin. This differentiation pattern is similar to that of virus-specific CD8 + T cells in patients undergoing an acute virus infection in the absence of HLH. In CMV infection, the percentage of CD127 − cells correlates with the level of viral replication [34] and incomplete virus control increases the fraction of CD57 + CD8 + T cells [26] . CD57 defines T cells with a high lytic granule content and cytotoxic activity [27] . Thus, the CD8 + T cell phenotype that was highly represented in 1°HLH and 2°V-HLH (CCR7 − CD45RA − CD127 − HLA-DR + PD-1 + CD57 + and perforin + ) is a phenotype that is also observed in patients with highly active, uncontrolled viral infections in the absence of features of HLH [35] [36] [37] .

Interestingly, however, in our study, only 3 of 31 infants with 1°HLH had a proven concomitant viral infection and apart from 1 patient with periungual S. aureus infection, no bacterial or opportunistic infections were detected. This was less than expected from a previously reported cohort of 122 patients with HLH, in which 25 patients with a positive family history were reported to have 

CD4 + ---an infectious trigger [5] . Obviously, although in most patients an extensive search for systemic viral infections including EBV, CMV, adenovirus, HHV-6, and HHV-8 and Parvovirus has been performed, these investigations do not rule out all infections, particularly with respiratory or gastrointestinal viruses. It is unclear, however, whether a local infection without systemic spread is sufficient to trigger and maintain the very strong systemic T-cell activation observed in 1°HLH. At least in perforin-deficient PKO mice, only systemic persistent infection with LCMV or MCMV can induce HLH [12, 38] , while local infections with respiratory viruses (RSV, pneumonia virus of mice, influenza) do not cause HLH in PKO mice [39] . Overall, it therefore remains a relevant possibility that the highly activated T-cell phenotype observed in human 1°HLH is in most cases not driven by a persisting viral (or other microbial) infection. This would imply that in humans, perforin-mediated control of T-cell stimulation is required for maintenance of T-cell homeostasis even in the absence of continued viral stimulation. Such pathophysiological differences between 1°HLH and 2°V-HLH are also suggested by a different pattern of CD4 + T cell activation in the two conditions. In 1°HLH, the percentage of CD4 + T cells with a highly activated HLA-DR + CD127 − PD1 + CD57 + perforin + phenotype was higher than in 2°V-HLH. Although perforin-expressing CD4 + T cells with cytotoxic activity have been described in persistent virus infections such as HIV, EBV and CMV infections [28, 40] in none of these conditions these cells reach the levels we observed in primary HLH. The stronger activation of CD4 + T cells in 1°HLH than in 2°V-HLH suggests qualitative differences in the activation of Tcell populations. Thus, the cytotoxicity defect and the associated impaired elimination of stimulating APC [41] could favor additional recruitment of CD4 + T cells into the inflammatory response through prolonged presentation of antigen via MHC class II. What is the function of the cytotoxic CD4 + T cells? It has been speculated that they play a role in containing viral infections tropic for MHC class II positive cells such as EBV in B cells [40] . They could also take over a prominent role in antiviral responses to pathogens that have evolved mechanisms to evade antigen presentation on MHC class I molecules [42] . However, in view of the above considerations, it is also conceivable that these cytotoxic CD4 + T cells have a role in human T-cell homeostasis that is independent of infection control, e.g. by controlling APC [41] .

A relevant number of infants without cytotoxicity defects fulfilling all current diagnostic criteria for HLH in the absence of an infection had mostly naive CD4 + and CD8 + T cells with very few cells expressing markers of activation or advanced differentiation. They all had sCD25 levels in the range of 5000-12 000 U/mL, but it is well known that immune cells other than T cells as well as non-immune cells [23] can significantly contribute to sCD25 production. In fact, we have recently documented similar sCD25 levels in immunodeficient patients fulfilling clinical HLH criteria that completely lacked T and NK cells [6] . In the current study, we have formally labeled these patients as 2°HLH, but as discussed previously, it is questionable whether the hemophagocytic inflammatory syndrome in these patients should really be called HLH. This study further illustrates, that the current clinical criteria for HLH cannot differentiate between T cell driven disease ("bona fide" HLH) and hemophagocytic syndromes without T-cell activation [6] . Because of obvious implications for therapy, in particular if targeting T cells, a revision and prospective validation of the diagnostic criteria is needed. Our data suggest that inclusion of markers of T-cell activation should be considered. Their use may help avoid too aggressive treatment of patients that according to current criteria are inappropriately classified as suffering from "lymphocytic" histiocytosis.

Patients were recruited to this project through the HLH study of the German Society of Pediatric Hematology and Oncology, details of which have been described elsewhere (Ammann et al., in preparation). The study was carried out after obtaining institutional review board approval (University of Freiburg ethics committee's protocol numbers 143/12 and 40/08). Control samples from healthy donors under 1 year of age were obtained from a clinic of HIV exposed (but not infected) infants (ethics number 282/11).

Patient inclusion required active HLH at the time of blood sampling, i.e. at least 5 of the 8 criteria defined by the Histiocyte Society. Patients who had received steroids for > 3 days or patients who had received cyclosporine or etoposide were excluded. All patients had microbiological investigations. Recommendations included blood cultures and screening for EBV, CMV, Adenovirus, HHV-6, and HHV-8 and Parvovirus by serology and PCR, but the extent of these investigations was not controlled in this study. As described (Ammann et al., in preparation), all patients had degranulation assays with "fresh" (uncultured) and "activated" (incubated with 100 U/mL IL-2 for 48-72 h) NK cells [43] . In parallel, stains for perforin, SAP and XIAP expression were performed. DNA from patients with abnormal protein expression was sequenced for mutations in PRF1, SH2D1A or BIRC4A. In patients with abnormal degranulation we analyzed UNC13D, including selected intronic regions [44, 45] , STXBP2 and STX11 [46] . In patients with albinism we sequenced RAB27A, LYST, and AP3B1. Exome sequencing was performed in unresolved cases with defective fresh NK degranulation as described [47] .

Patients with reduced perforin expression or defective NK cell degranulation and biallelic mutations in a gene associated with FHL2-5, CHS, or GS2 were classified as 1°HLH. Patients with XLP or malignant disease were excluded. Patients who had negative genetic results including patients with monoallelic variants but no immunological abnormalities or patients in whom no genetic analysis was performed, were classified as 2°HLH, if they did not have a disease relapse for at least 6 months after the first HLH episode (median follow-up 2.3 (0.5 -4.5) years). Among these, patients who developed HLH in the context of a documented viral infection, were classified as 2°virus-induced HLH (2°V-HLH). The other patients who developed HLH with or without underlying disease without evidence for an infection were classified as 2°HLH. Patients who could not be clearly assigned to one of these groups were excluded.

Siblings identified at birth with biallelic mutations in HLHassociated genes, but without clinical symptoms were included to control for possible alterations in the T cell phenotype due to the genetic defect in the absence of an acute HLH episode (asymptomatic 1°HLH). A group of HIV exposed (but not infected) infants under 1 year of age was included as healthy controls.

HLA-DR expression on CD3 + CD8 + and CD3 + CD4 + T cells and sCD25 levels Chemiluminescence Immunoassay (CLIA) were measured in all patients referred for suspected HLH. Since the age-independent variability of HLA-DR expression and sCD25 level in healthy donors is limited, patients of all ages fulfilling the inclusion criteria were considered for analysis (n = 93). For all other investigations, we only included patients younger than one year because of the extensive variability in T-cell differentiation marker expression beyond that age. In that group, ficoll isolated PBMCs were stained with three different stainings using the antibodies indicated in the Supporting Information material.

Data were analyzed by Mann-Whitney U test using GraphPad Prism version 6.00 for Windows, GraphPad Software, San Diego California USA, www.graphpad. Significance was defined as * for p ࣘ0.05, ** for p ࣘ0.005, *** for p ࣘ 0.0005, and **** for p < 0.0001.

The authors would like to thank the patients and their families as well as all physicians participating in the GPOH HLH study. We are grateful to the team of the CCI Advanced Diagnostic Unit for their excellent work. This work was supported by grants from the DFG (SFB1160, TP1) and BMBF (01 EO 0803) to S.E. The following physicians contributed substantially to the

Gunnar Cario (Kiel), Carl-Friedrich Classen (Rostock)

Kai Lehmberg: coordinates the GPOH HLH study, collected patient data

Udo zur Stadt: performed sequencing and provided genetic data

Gritta Janka: initiated GPOH study, collected patient data; Anne Rensing-Ehl: performed experiments; Christian Klemann: collected patient data

Maximilian Heeg: performed ROC analysis

collected patient data; Ilka Fuchs: coordinated diagnostic testing; Stephan Ehl: designed the study, coordinates the GPOH HLH study, drafted manuscript Conflicts of interest: S.E. has received consulting fees from UCB and Novartis, but not in relation to this study

Familial and acquired hemophagocytic lymphohistiocytosis

Inherited defects in lymphocyte cytotoxic activity

Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism

X-linked lymphoproliferative syndromes and related autosomal recessive disorders

Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society

The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis

Genetic predisposition to hemophagocytic lymphohistiocytosis: report on 500 patients from the Italian registry

Targeted high-throughput sequencing for genetic diagnostics of hemophagocytic lymphohistiocytosis

Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents

Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6-and TNF-alpha-producing macrophages

Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis

An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder

Perforin is a critical physiologic regulator of T-cell activation

Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr. Blood Cancer

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro

Ia determinants on stimulated human T lymphocytes. Occurrence on mitogenand antigen-activated T cells

Peripheral human T cells sensitized in mixed leukocyte culture synthesize and express Ia-like antigens

Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations

Refined characterization and reference values of the pediatric T-and B-cell compartments

The role of interleukin-2 during homeostasis and activation of the immune system

Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A

Human memory T cells: generation, compartmentalization and homeostasis

Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells

Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production

Characterization of CD4(+) CTLs ex vivo

Evolution of the CD8 T-cell repertoire during infections. Microbes Infect

Inflammatory cytokines in virus-associated hemophagocytic syndrome. Interferon-gamma as a sensitive indicator of disease activity

Heterogeneity of immune markers in hemophagocytic lymphohistiocytosis: comparative study of 9 familial and 14 familial inheritanceunproved cases

Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis

A prospective study of CD45 isoform expression in haemophagocytic lymphohistiocytosis; an abnormal inherited immunophenotype in one family

IL-7 receptor alpha chain expression distinguishes functional subsets of virus-specific human CD8+ T cells

Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection

Human CD8(+) T-cell differentiation in response to viruses

PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status

Perforin and granzymes have distinct roles in defensive immunity and immunopathology

Composition and efficacy of cytotoxic T cell responses determine virus elimination and immunopathology after virus infections. Dissertation university of Freiburg

Cytotoxic human CD4(+) T cells

Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells

Emergence of a CD4+CD28-granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection

A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes

Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D

Novel deep intronic and missense UNC13D mutations in familial haemophagocytic lymphohistiocytosis type 3

Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11

Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome

Abbreviations: ATG: anti-thymocyte globulin · CD: cluster of differentation · CHS: Chediak-Higashi Syndrome · CMV: Cytomegalovirus · CTL: cytotoxic T cell · EBV: Epstein-Bar Virus · FHL: familial HLH type · GM-CSF: Granulocyte-macrophage colony-stimulating factor · GS

Macropahge activation syndrome · MHC: Major histocompatibilty complex · PCR: polymerase chain reaction · PD-1: Programmed cell death protein 1 · SAP: Slam-associated protein · sCD25: soluble IL-2 receptor · TCM: central memory T cells · TCR: T-cell receptor · TE: terminally differentiated or effector · TEM: effector memory T cells · V-HLH: viral induced HLH · XIAP: X-linked inhibitor of apoptosis · XLP: linked lymphoproliferative disease Full correspondence: Dr